Larazotide

Larazotide, also known as AT-1001, is an oral peptide designed specifically to work inside the gut without being absorbed into the bloodstream. It was developed to address one of the core mechanisms behind intestinal permeability - often called leaky gut - by reinforcing the connections between gut-lining cells. How it works: Larazotide restores tight junctions in the intestinal wall. Tight junctions are the physical seals between the cells lining the gut, and when they degrade, unwanted substances can pass from the gut into the body and trigger immune responses. Larazotide acts locally to tighten these connections back up. Because it is not absorbed, its action stays in the gut. Who tends to use it: Larazotide has been studied most in celiac disease, where intestinal permeability is a central problem. More broadly it is considered for anyone dealing with gut-lining dysfunction, inflammatory bowel conditions, or immune activation tied to gut barrier issues. Its primary goal weight is gut health, with immune support as a secondary target. What to expect: Larazotide works on the structural integrity of the gut lining rather than suppressing symptoms directly. Its effects build over the course of weeks of consistent use. How it is taken: Larazotide is taken orally at a dose of 0.5 mg, before meals - specifically about 15 minutes before eating. The meal-timing component is important because gut permeability often spikes in response to food intake. Protocols run 4-12 weeks. Safety notes: Because larazotide acts locally in the gut with minimal systemic absorption, it has a favorable safety profile. There are no exclusion flags for pregnancy or cancer history. It is an investigational compound. It pairs well with BPC-157 and KPV in gut-focused protocols. Your protocol length and the combination of gut-support peptides right for you are determined at a PepDepo consultation.